Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pioneering pharmaceutical company dedicated to delivering impactful advancements in patient care through innovative science and advanced delivery technologies, has announced its participation in the 76th Annual Meeting of the American Academy of Neurology (AAN). The event, scheduled to take place from April 13 to 18 in Denver, will offer both in-person attendance and live online participation through a hybrid format. During this significant gathering of neurology professionals, Aquestive will present a poster highlighting the promising results of its crossover study for the product candidate, Libervant (diazepam) Buccal Film, aimed at children aged two to five suffering from epilepsy.
Libervant Buccal Film, developed by Aquestive Therapeutics, represents a potential breakthrough in the treatment of pediatric epilepsy. Administered via buccal film, it offers a convenient, dissolvable dosage form that has shown significant promise in managing seizures and providing relief for young epilepsy patients. The crossover study, presented at the AAN Annual Meeting, aimed to evaluate the safety and effectiveness of Libervant in this specific age group.
The study results demonstrate encouraging findings, indicating that Libervant Buccal Film effectively reduced both the frequency and duration of seizures among children aged two to five. These findings hold significant promise for improving the quality of life for both patients and their caregivers. The innovative delivery technology employed by Aquestive Therapeutics has proven to be a safe and reliable method for administering the medication, ensuring convenience and ease of use for both patients and healthcare providers.
As Aquestive Therapeutics continues to prioritize innovation and patient-centric solutions, the presentation of the crossover study at the AAN Annual Meeting underscores the company’s dedication to advancing epilepsy treatment options for children. With epilepsy posing significant challenges for pediatric patients and their families, the potential of Libervant Buccal Film offers hope for a brighter future.
The AAN Annual Meeting provides an ideal platform for Aquestive Therapeutics to share their groundbreaking research and engage in discussions with leading neurologists and healthcare professionals. With the event offering a hybrid format this year, experts from around the world can participate in real-time while adhering to travel restrictions and safety concerns.
Aquestive Therapeutics’ participation in the AAN Annual Meeting reflects their commitment to revolutionizing treatment options and improving the lives of patients suffering from epilepsy. As the company continues to explore the potential of Libervant Buccal Film, their dedication to innovative science and delivery technologies remains resolute.
Comments